Sign up online today & collaborate
or click here to find out more
Isansys Lifecare Ltd is proud to announce it has been shortlisted for the Celebration of Innovation Awards 2017, a prestigious award celebrating the best of innovation in healthcare.
Isansys Lifecare Ltd has been selected in the “Economic Impact Award” and the “MidTECH Award for… Best NHS Invention or Innovation” categories of the West Midlands Academic Health Science Network (WMAHSN)’s second annual Celebration of Innovation awards. This will be held at the Hilton Metropole at Birmingham’s NEC next week (July 20th)
Isansys has created the Patient Status Engine (PSE), a wireless, remote patient monitoring platform which collects and analyses patient vital signs remotely.
For the first time ever, the PSE is allowing healthcare professionals to care for their patients both in hospital, in the community and at home and is providing clinicians access to real-time, continuous and predictive data which they can use to act quickly and save lives.
The PSE uses wireless, wearable sensors including the Isansys’ Lifetouch cardiac monitoring smart patch and the Lifetemp wireless thermometer to monitor patients freely of cables and wires ensuring any deterioration in the condition of a patient is identified more quickly and timely treatment is given.
Keith Errey, CEO of Isansys, which is based in Oxfordshire, says: “It's a great honour for Isansys to be shortlisted for two categories of the Celebration of Innovation Awards 2017. This is clear recognition that the work we are doing in deploying our Patient Status Engine, patient monitoring platform, to hospital and healthcare providers is very much the future of healthcare.”
Dr Christopher Parker, Managing Director of the WMAHSN, said: “We are delighted that Isansys Lifecare Ltd has been shortlisted for our awards.”
The awards, which were established to recognise and celebrate the work of individuals and organizations in developing better healthcare and increasing wealth for local people, will highlight the innovative nature of the PSE and showcase Isansys’ work at the Birmingham Children’s and Women’s Hospital, where it has monitored more than 1,000 patients.